Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
- Author
- OLIN, Jason T1 ; BHATNAGAR, Vinod2 ; REYES, Patricio3 ; KOUMARAS, Barbara1 ; XIANGYI MENG1 ; BRANNAN, Stephen4
[1] Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
[2] Center for Clinical Trials and Research, Inc., Venice, FL, United States
[3] Barrow Neurological Institute, Phoenix, AZ, United States
[4] Takeda Pharmaceuticals North America, (formerly Novartis Pharmaceuticals Corporation), Deerfield, IL, United States - Source
International journal of geriatric psychiatry. 2010, Vol 25, Num 4, pp 419-426, 8 p ; ref : 1/4 p
- ISSN
- 0885-6230
- Scientific domain
- Cognition; Psychology, psychopathology, psychiatry
- Publisher
- Psychology Press, Hove
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Alzheimer's disease cholinesterase inhibitor dementia memantine rivastigmine tolerability
- Keyword (fr)
- Antialzheimer Anticholinestérasique Antiparkinsonien Association médicamenteuse Capsule Démence d'Alzheimer Efficacité traitement Environnement social Essai clinique Etude longitudinale Forme pharmaceutique Mémantine Nootrope Personne âgée Pharmacothérapie Psychotrope Rivastigmine Santé mentale Santé publique Toxicité Essai ouvert Essai thérapeutique Etats-Unis Acetylcholinesterase Antagoniste Carboxylic ester hydrolases Dérivé de l'amantadine Enzyme Esterases Homme Hydrolases Inhibiteur enzyme Maladie dégénérative Pathologie de l'encéphale Pathologie du système nerveux central Pathologie du système nerveux Récepteur NMDA Récepteur glutamate Traitement Amérique du Nord Amérique
- Keyword (en)
- Antialzheimer agent Anticholinesterase agent Antiparkinson agent Drug combination Capsule Alzheimer disease Treatment efficiency Social environment Clinical trial Follow up study Dosage form Memantine Nootropic agent Elderly Pharmacotherapy Psychotropic Rivastigmine Mental health Public health Toxicity United States Acetylcholinesterase Antagonist Carboxylic ester hydrolases Amantadine derivatives Enzyme Esterases Human Hydrolases Enzyme inhibitor Degenerative disease Cerebral disorder Central nervous system disease Nervous system diseases NMDA receptor Glutamate receptor Treatment North America America
- Keyword (es)
- Antialzheimer Anticolinesterasa agente Antiparkinsoniano Asociación medicamentosa Cápsula Demencia Alzheimer Eficacia tratamiento Contexto social Ensayo clínico Estudio longitudinal Forma farmacéutica Memantina Nootropo Anciano Farmacoterapia Psicotropo Rivastigmina Salud mental Salud pública Toxicidad Estados Unidos Acetylcholinesterase Antagonista Carboxylic ester hydrolases Amantadina derivada Enzima Esterases Hombre Hydrolases Inhibidor enzima Enfermedad degenerativa Encéfalo patología Sistema nervosio central patología Sistema nervioso patología Receptor NMDA Receptor glutámato Tratamiento America del norte America
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology / 002B02B02 Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02U Drug toxicity and drugs side effects treatment / 002B02U10 Miscellaneous (drug allergy, mutagens, teratogens...)
- Francis
- 770 Psychology. Psychoanalysis. Psychiatry / 770-E Psychopharmacology / 770-E02 Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer…
- Discipline
- Drugs toxicity and drug intoxications Pharmacological treatments Psychopathology. Psychiatry. Clinical psychology Toxicology
- Origin
- Inist-CNRS
- Database
- FRANCIS ; PASCAL
- INIST identifier
- 22530306
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1002/gps.2355 
https://dx.doi.org/10.1002/gps.2355
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:16:\"10.1002\/gps.2355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"International journal of geriatric psychiatry\";s:9:\"\u0000*\u0000stitle\";s:27:\"Int. j. geriatr. psychiatry\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"419\";s:8:\"\u0000*\u0000epage\";s:3:\"426\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-6230\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"OLIN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Jason T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:16:\"BHATNAGAR, Vinod\";i:1;s:15:\"REYES, Patricio\";i:2;s:17:\"KOUMARAS, Barbara\";i:3;s:12:\"XIANGYI MENG\";i:4;s:16:\"BRANNAN, Stephen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:8:\"\u0000*\u0000place\";s:4:\"Hove\";s:6:\"\u0000*\u0000pub\";s:16:\"Psychology Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:16:\"10.1002\/gps.2355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"International journal of geriatric psychiatry\";s:9:\"\u0000*\u0000stitle\";s:27:\"Int. j. geriatr. psychiatry\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"419\";s:8:\"\u0000*\u0000epage\";s:3:\"426\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-6230\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"OLIN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Jason T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:16:\"BHATNAGAR, Vinod\";i:1;s:15:\"REYES, Patricio\";i:2;s:17:\"KOUMARAS, Barbara\";i:3;s:12:\"XIANGYI MENG\";i:4;s:16:\"BRANNAN, Stephen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:8:\"\u0000*\u0000place\";s:4:\"Hove\";s:6:\"\u0000*\u0000pub\";s:16:\"Psychology Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:16:\"10.1002\/gps.2355\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:16:\"10.1002\/gps.2355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"International journal of geriatric psychiatry\";s:9:\"\u0000*\u0000stitle\";s:27:\"Int. j. geriatr. psychiatry\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"419\";s:8:\"\u0000*\u0000epage\";s:3:\"426\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-6230\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"OLIN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Jason T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:16:\"BHATNAGAR, Vinod\";i:1;s:15:\"REYES, Patricio\";i:2;s:17:\"KOUMARAS, Barbara\";i:3;s:12:\"XIANGYI MENG\";i:4;s:16:\"BRANNAN, Stephen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:8:\"\u0000*\u0000place\";s:4:\"Hove\";s:6:\"\u0000*\u0000pub\";s:16:\"Psychology Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:16:\"10.1002\/gps.2355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"International journal of geriatric psychiatry\";s:9:\"\u0000*\u0000stitle\";s:27:\"Int. j. geriatr. psychiatry\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"419\";s:8:\"\u0000*\u0000epage\";s:3:\"426\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-6230\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"OLIN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Jason T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:16:\"BHATNAGAR, Vinod\";i:1;s:15:\"REYES, Patricio\";i:2;s:17:\"KOUMARAS, Barbara\";i:3;s:12:\"XIANGYI MENG\";i:4;s:16:\"BRANNAN, Stephen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:8:\"\u0000*\u0000place\";s:4:\"Hove\";s:6:\"\u0000*\u0000pub\";s:16:\"Psychology Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:16:\"10.1002\/gps.2355\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:9:\"\u0000*\u0000jtitle\";s:45:\"International journal of geriatric psychiatry\";s:9:\"\u0000*\u0000stitle\";s:27:\"Int. j. geriatr. psychiatry\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"419\";s:8:\"\u0000*\u0000epage\";s:3:\"426\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0885-6230\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"OLIN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Jason T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:16:\"BHATNAGAR, Vinod\";i:1;s:15:\"REYES, Patricio\";i:2;s:17:\"KOUMARAS, Barbara\";i:3;s:12:\"XIANGYI MENG\";i:4;s:16:\"BRANNAN, Stephen\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:171:\"Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)\";s:8:\"\u0000*\u0000place\";s:4:\"Hove\";s:6:\"\u0000*\u0000pub\";s:16:\"Psychology Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
